BRPI9911326B8 - análogos macrocíclicos e métodos para seu uso e preparação - Google Patents

análogos macrocíclicos e métodos para seu uso e preparação

Info

Publication number
BRPI9911326B8
BRPI9911326B8 BRPI9911326A BR9911326A BRPI9911326B8 BR PI9911326 B8 BRPI9911326 B8 BR PI9911326B8 BR PI9911326 A BRPI9911326 A BR PI9911326A BR 9911326 A BR9911326 A BR 9911326A BR PI9911326 B8 BRPI9911326 B8 BR PI9911326B8
Authority
BR
Brazil
Prior art keywords
methods
preparation
analogues
macrocyclic
cell
Prior art date
Application number
BRPI9911326A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9911326A (pt
BR9911326B1 (pt
Inventor
M Seletsky Boris
A Littlefield Bruce
j yu Melvin
Palme Monica
J Towle Murray
Zheng Wanjun
Original Assignee
Eisai Co Ltd
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9911326(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd, Eisai R&D Man Co Ltd filed Critical Eisai Co Ltd
Publication of BR9911326A publication Critical patent/BR9911326A/pt
Publication of BR9911326B1 publication Critical patent/BR9911326B1/pt
Publication of BRPI9911326B8 publication Critical patent/BRPI9911326B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI9911326A 1998-06-17 1999-06-16 análogos macrocíclicos e métodos para seu uso e preparação BRPI9911326B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17
US60/089,682 1998-06-17
PCT/US1999/013677 WO1999065894A1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation

Publications (3)

Publication Number Publication Date
BR9911326A BR9911326A (pt) 2001-04-03
BR9911326B1 BR9911326B1 (pt) 2015-01-06
BRPI9911326B8 true BRPI9911326B8 (pt) 2021-05-25

Family

ID=22219026

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9911326A BRPI9911326B8 (pt) 1998-06-17 1999-06-16 análogos macrocíclicos e métodos para seu uso e preparação

Country Status (22)

Country Link
US (4) US6214865B1 (https=)
EP (4) EP2277873B1 (https=)
JP (1) JP4454151B2 (https=)
KR (1) KR100798600B1 (https=)
CN (1) CN1216051C (https=)
AT (1) ATE502932T1 (https=)
AU (1) AU762998B2 (https=)
BE (1) BE2011C028I2 (https=)
BR (1) BRPI9911326B8 (https=)
CA (3) CA2755266C (https=)
CY (2) CY1111516T1 (https=)
DE (2) DE122011100031I1 (https=)
DK (1) DK1087960T3 (https=)
FR (1) FR11C0038I2 (https=)
HU (1) HU227912B1 (https=)
IL (1) IL139960A0 (https=)
LU (1) LU91854I2 (https=)
NO (5) NO328280B1 (https=)
NZ (1) NZ508597A (https=)
PT (1) PT1087960E (https=)
WO (1) WO1999065894A1 (https=)
ZA (1) ZA200007159B (https=)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US6214865B1 (en) * 1998-06-17 2001-04-10 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
AU2003228354B8 (en) 2002-03-22 2010-03-04 Eisai R&D Management Co., Ltd. Hemiasterlin derivatives and uses thereof in the treatment of cancer
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
EP1644008B1 (en) * 2003-05-29 2011-12-21 Abbott Laboratories Continuous dosing regimen with abt-751
EP1653953A4 (en) * 2003-07-29 2010-05-05 Eisai R&D Man Co Ltd METHOD AND DEVICES FOR THE MEDICINAL PRODUCTION
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
CA2822994C (en) * 2004-06-03 2016-09-27 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
EP1831697A4 (en) * 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd SEARCH FOR TUBULINISOTYPES IN CANCER THERAPY USING HALICHONDRIN B ANALOG
RU2489437C2 (ru) * 2007-10-03 2013-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Промежуточные соединения и способы синтеза аналогов галихондрина в
CN105801599A (zh) * 2008-04-04 2016-07-27 卫材R&D管理有限公司 软海绵素b类似物
EP2415464B1 (en) 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
RU2476216C1 (ru) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
ES2593027T3 (es) 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
EP2420504B1 (en) * 2009-04-14 2014-01-15 Nissan Chemical Industries, Ltd. Method for producing tetrahydropyran compound and intermediate thereof
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
WO2011094339A1 (en) 2010-01-26 2011-08-04 Eisai R&D Management Co., Ltd. Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
EP2686441B1 (en) 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
EP2785687B1 (en) 2011-11-30 2019-02-20 Sandoz AG Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
CN104024237B (zh) 2011-12-16 2016-02-24 阿方拉研究股份有限公司 用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体
CN104080793B (zh) * 2011-12-29 2017-09-19 阿方拉研究股份有限公司 2‑((2s,3s,4r,5r)‑5‑((s)‑3‑氨基‑2‑羟基丙‑1‑基)‑4‑甲氧基‑3‑(苯磺酰甲基)四氢呋喃‑2‑基)乙醛衍生物以及它们的制备方法
WO2013142999A1 (en) * 2012-03-30 2013-10-03 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
MX2015007185A (es) 2012-12-04 2017-09-05 Eisai R&D Man Co Ltd Uso de eribulina en el tratamiento de cancer de pecho.
AR096238A1 (es) 2013-05-15 2015-12-16 Alphora Res Inc Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo
KR102265952B1 (ko) 2013-06-26 2021-06-16 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
CA2916537C (en) * 2013-07-03 2021-07-27 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
EP3689881B1 (en) 2013-11-04 2022-01-12 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
MX384292B (es) * 2013-12-06 2025-03-14 Eisai R&D Man Co Ltd Metodos utiles en la sintesis de analogos de halicondrina b.
CN104860978A (zh) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 软海绵素b类似物的合成中间体
TW201617326A (zh) * 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
RU2699545C2 (ru) * 2014-05-28 2019-09-06 ЭЙСАЙ Ар ЭНД Ди МЕНЕДЖМЕНТ КО., ЛТД Применение эрибулина в лечении рака
US10556910B2 (en) * 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
WO2016038624A1 (en) 2014-09-09 2016-03-17 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
CN105713031B (zh) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 一种用于制备艾日布林的中间体及其制备方法
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
CA2978311A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating cancer
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
KR102743950B1 (ko) 2015-05-07 2024-12-18 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤라이드의 합성에 유용한 마크로고리화 반응 및 중간체 및 기타 단편
WO2016182850A1 (en) 2015-05-08 2016-11-17 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
EP3413887B1 (en) * 2016-02-12 2021-04-07 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
US12029724B2 (en) 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
KR20190009326A (ko) * 2016-05-26 2019-01-28 닥터 레디스 레보러터리즈 리미티드 에리불린 및 그의 중간체의 제조방법
US11136335B2 (en) 2016-06-30 2021-10-05 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
BR112019007145A2 (pt) 2016-10-14 2019-07-02 Eisai R&D Man Co Ltd combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
CN110167536A (zh) * 2016-11-23 2019-08-23 雷迪博士实验室有限公司 艾日布林及其中间体的制备方法
KR101880939B1 (ko) 2017-01-02 2018-08-17 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
KR101991710B1 (ko) 2017-12-14 2019-06-21 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
JP6920699B2 (ja) * 2017-01-02 2021-08-18 ヨンスン ファイン ケミカル カンパニー，リミテッド エリブリンメシル酸塩の製造中間体及びその製造方法
CN108341828B (zh) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN108341738B (zh) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
ES2931533T3 (es) 2017-04-05 2022-12-30 Harvard College Compuesto macrocíclico y usos del mismo
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA
HUE061306T2 (hu) 2017-07-06 2023-06-28 Harvard College Halikondrinok szintézise
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
JP6967811B2 (ja) * 2017-11-09 2021-11-17 ヨンスン ファイン ケミカル カンパニー，リミテッド エリブリンメシル酸塩の製造中間体及びその製造方法
CN111566113B (zh) 2017-11-15 2024-01-09 哈佛大学的校长及成员们 大环化合物及其用途
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11008296B2 (en) 2017-11-21 2021-05-18 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
SG11202005548WA (en) 2018-01-03 2020-07-29 Eisai R&D Man Co Ltd Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
JP2021532102A (ja) * 2018-07-20 2021-11-25 ドクター レディズ ラボラトリーズ リミテッド エリブリンおよびその中間体の調製のための精製プロセス
EP3864011A4 (en) * 2018-10-09 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for preparation of eribulin and intermediates thereof
US12522611B2 (en) * 2018-11-28 2026-01-13 Natco Pharma Limited Process for the preparation of high pure Eribulin and its Mesylate salt
MX2021007562A (es) 2018-12-20 2021-09-28 Auransa Inc Analogos de pentamidina y usos para estos.
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
JP7574232B2 (ja) 2019-06-21 2024-10-28 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ ホモプロパルギルアルコールを調製するための化学酵素的プロセス
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
JP7657213B2 (ja) 2019-11-07 2025-04-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法
CN113135876B (zh) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 艾日布林及其中间体的制备方法
CN118949063A (zh) * 2020-01-22 2024-11-15 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
KR102377262B1 (ko) 2020-05-11 2022-03-22 연성정밀화학(주) 결정성 에리불린 염
IL279168B (en) * 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd A process for the preparation of eribulin
CN113354659B (zh) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
AU2022316425A1 (en) * 2021-07-22 2024-02-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Drug conjugate of eribulin derivative
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
KR20250133788A (ko) * 2023-01-17 2025-09-08 시스트이뮨, 인코포레이티드 에리불린 약물 접합체
EP4725969A1 (en) 2023-06-09 2026-04-15 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof
CN118834221B (zh) * 2023-08-08 2025-10-21 浙江星月药物科技有限公司 一种软海绵素b类似物
TW202518024A (zh) 2023-10-13 2025-05-01 日商衛材R&D企管股份有限公司 抗體－藥物軛合物代謝物
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof
WO2025228172A1 (zh) * 2024-04-28 2025-11-06 上海拓济医药有限责任公司 艾日布林衍生物及其抗体药物偶联物和医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US6214865B1 (en) 1998-06-17 2001-04-10 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
RU2489437C2 (ru) 2007-10-03 2013-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Промежуточные соединения и способы синтеза аналогов галихондрина в
RU2010118063A (ru) * 2007-11-16 2011-12-27 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Новое промежуточное соединение для синтеза аналога галихондрина в и новая реакция десульфонилирования, применяемая для получения промежуточного соединения
CN105801599A (zh) * 2008-04-04 2016-07-27 卫材R&D管理有限公司 软海绵素b类似物
WO2011094339A1 (en) 2010-01-26 2011-08-04 Eisai R&D Management Co., Ltd. Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs

Also Published As

Publication number Publication date
EP1087960B1 (en) 2011-03-23
BR9911326A (pt) 2001-04-03
DK1087960T3 (da) 2011-06-14
US20110172446A1 (en) 2011-07-14
EP2277873A1 (en) 2011-01-26
NO20006316L (no) 2001-02-15
NO2011018I1 (no) 2011-09-26
FR11C0038I2 (fr) 2013-01-11
KR20010083050A (ko) 2001-08-31
NZ508597A (en) 2004-01-30
RU2245335C2 (ru) 2005-01-27
EP1087960A4 (en) 2004-12-01
HU227912B1 (en) 2012-05-29
CA2335300A1 (en) 1999-12-23
HUP0103357A2 (hu) 2002-01-28
NO20006316D0 (no) 2000-12-12
NO2011026I2 (no) 2012-06-11
CY1111516T1 (el) 2014-04-09
EP2272839B1 (en) 2012-08-22
CA2632433C (en) 2012-02-07
IL139960A0 (en) 2002-02-10
AU4573999A (en) 2000-01-05
NO2022019I1 (no) 2022-06-03
DE122011100031I1 (de) 2011-12-15
JP4454151B2 (ja) 2010-04-21
BE2011C028I2 (en) 2018-08-24
CA2632433A1 (en) 1999-12-23
EP1087960A1 (en) 2001-04-04
LU91854I2 (fr) 2011-10-17
CN1312804A (zh) 2001-09-12
EP2272840A1 (en) 2011-01-12
US6365759B1 (en) 2002-04-02
PT1087960E (pt) 2011-06-17
US6469182B1 (en) 2002-10-22
CN1216051C (zh) 2005-08-24
CA2755266C (en) 2014-08-12
NO2011026I1 (no) 2012-01-09
BR9911326B1 (pt) 2015-01-06
HUP0103357A3 (en) 2002-10-28
WO1999065894A1 (en) 1999-12-23
AU762998C (en) 2000-01-05
US6214865B1 (en) 2001-04-10
CY2011010I1 (el) 2014-04-09
CA2755266A1 (en) 1999-12-23
CA2335300C (en) 2008-10-07
ATE502932T1 (de) 2011-04-15
EP2272839A1 (en) 2011-01-12
ZA200007159B (en) 2001-12-04
NO20093217L (no) 2001-02-15
FR11C0038I1 (fr) 2011-10-14
NO331183B1 (no) 2011-10-24
EP2277873B1 (en) 2012-05-30
AU762998B2 (en) 2003-07-10
HK1035534A1 (en) 2001-11-30
CY2011010I2 (el) 2014-04-09
KR100798600B1 (ko) 2008-01-28
US8148554B2 (en) 2012-04-03
JP2002518384A (ja) 2002-06-25
EP2272840B1 (en) 2012-08-22
NO328280B1 (no) 2010-01-25
DE69943296D1 (de) 2011-05-05

Similar Documents

Publication Publication Date Title
BRPI9911326B8 (pt) análogos macrocíclicos e métodos para seu uso e preparação
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BENCOSME et al. Electron microscopy of the pancreatic islets
BR9811249A (pt) Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 à 0,38g/ml, processo para preparação de formulação e uso da mesma
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
BR0113358A (pt) Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável
BR0109705A (pt) Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
PA8515701A1 (es) Compuestos, composiciones farmaceuticas y metodos para inhibir kinasas proteinicas
BR9808703A (pt) Composição que fornece medicamento solúvel emágua de dissolução relativamente lenta e usosublingual
ES2193391T3 (es) Antagonistas muscarinicos.
BR9708632A (pt) Composto calcilìticos
BR9810729A (pt) Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante
GT199700089A (es) Derivados 6.6 o 6.7 -biciclicos sustituidos que contienen pirido o pirimido.
BRPI0206636B8 (pt) composição e atividade antiviral de derivados de piperazina azaindoloxoacéticos substituídos, composições farmacêuticas que os contêm e usos
BR9713694A (pt) Artigo absorvente com barreiras de contenção longitudinais tridimensionais
BR0006675A (pt) Derivados de indoloxoacetil piperazina antivirais
BR0108930A (pt) Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente
BR9803704A (pt) Quinazolina-4-ona como antagonistas do ampa.
BR0316296A (pt) Compostos lapacone e seus métodos de uso
BR0210630A (pt) Sistema fornecedor de liberação prolongada
BR9814756A (pt) Composição sólida seca para liberação de droga, processo para a preparação da mesma, uso de um grande número de pequenas esferas que contêm uma matriz polimérica composta de um polietileno glicol ou de uma mistura de polietileno glicóis
ATE192338T1 (de) Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen
BR9809057A (pt) Composições antitussìgenas
BR9811458A (pt) "sistema solvente para penetração melhorada de compostos farmacêuticos"

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: EISAI RANDD MANAGEMENT CO., LTD. (JP)

Free format text: TRANSFERIDO DE: EISAI CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/01/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/06/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 16/06/2019